%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3eIcon/Menu%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cdefs%3e%3cpolygon%20id='path-1'%20points='0.0005%200.646%2022.386%200.646%2022.386%203.1455%200.0005%203.1455'%3e%3c/polygon%3e%3cpolygon%20id='path-3'%20points='0.0005%200.9341%2022.386%200.9341%2022.386%203.4341%200.0005%203.4341'%3e%3c/polygon%3e%3cpolygon%20id='path-5'%20points='0.0005%200.5%2022.386%200.5%2022.386%203%200.0005%203'%3e%3c/polygon%3e%3c/defs%3e%3cg%20id='Symbols'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='Icon/Menu'%3e%3cg%20id='Group-10-Copy'%20transform='translate(3.800000,%205.300000)'%3e%3cg%20id='Group-3'%20transform='translate(0.000000,%200.354500)'%3e%3cmask%20id='mask-2'%20fill='white'%3e%3cuse%20xlink:href='%23path-1'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpath%20d='M22.3865,2.6455%20C22.3865,2.9205%2022.1615,3.1455%2021.8865,3.1455%20L0.5005,3.1455%20C0.2245,3.1455%200.0005,2.9205%200.0005,2.6455%20L0.0005,1.1455%20C0.0005,0.8705%200.2245,0.6455%200.5005,0.6455%20L21.8865,0.6455%20C22.1615,0.6455%2022.3865,0.8705%2022.3865,1.1455%20L22.3865,2.6455%20Z'%20id='Fill-1'%20fill='%23FFFFFF'%20mask='url(%23mask-2)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-6'%20transform='translate(0.000000,%207.354500)'%3e%3cmask%20id='mask-4'%20fill='white'%3e%3cuse%20xlink:href='%23path-3'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-5'%3e%3c/g%3e%3cpath%20d='M22.3865,2.9341%20C22.3865,3.2091%2022.1615,3.4341%2021.8865,3.4341%20L0.5005,3.4341%20C0.2245,3.4341%200.0005,3.2091%200.0005,2.9341%20L0.0005,1.4341%20C0.0005,1.1591%200.2245,0.9341%200.5005,0.9341%20L21.8865,0.9341%20C22.1615,0.9341%2022.3865,1.1591%2022.3865,1.4341%20L22.3865,2.9341%20Z'%20id='Fill-4'%20fill='%23FFFFFF'%20mask='url(%23mask-4)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-9'%20transform='translate(0.000000,%2015.354500)'%3e%3cmask%20id='mask-6'%20fill='white'%3e%3cuse%20xlink:href='%23path-5'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-8'%3e%3c/g%3e%3cpath%20d='M22.3865,2.5%20C22.3865,2.775%2022.1615,3%2021.8865,3%20L0.5005,3%20C0.2245,3%200.0005,2.775%200.0005,2.5%20L0.0005,1%20C0.0005,0.725%200.2245,0.5%200.5005,0.5%20L21.8865,0.5%20C22.1615,0.5%2022.3865,0.725%2022.3865,1%20L22.3865,2.5%20Z'%20id='Fill-7'%20fill='%23FFFFFF'%20mask='url(%23mask-6)'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23fff'%20fill-rule='nonzero'%3e%3cg%20id='icon/fold'%20transform='translate(240.000000,%20272.000000)'%3e%3cpath%20d='M11.5,2.3%20C6.4216,2.3%202.3,6.4216%202.3,11.5%20C2.3,16.5784%206.4216,20.7%2011.5,20.7%20C16.5784,20.7%2020.7,16.5784%2020.7,11.5%20C20.7,6.4216%2016.5784,2.3%2011.5,2.3%20Z%20M10.58,18.7956%20C6.946,18.3448%204.14,15.2536%204.14,11.5%20C4.14,10.9296%204.2136,10.3868%204.3332,9.8532%20L8.74,14.26%20L8.74,15.18%20C8.74,16.192%209.568,17.02%2010.58,17.02%20L10.58,18.7956%20Z%20M16.928,16.4588%20C16.6888,15.7136%2016.008,15.18%2015.18,15.18%20L14.26,15.18%20L14.26,12.42%20C14.26,11.914%2013.846,11.5%2013.34,11.5%20L7.82,11.5%20L7.82,9.66%20L9.66,9.66%20C10.166,9.66%2010.58,9.246%2010.58,8.74%20L10.58,6.9%20L12.42,6.9%20C13.432,6.9%2014.26,6.072%2014.26,5.06%20L14.26,4.6828%20C16.9556,5.7776%2018.86,8.418%2018.86,11.5%20C18.86,13.4136%2018.124,15.1524%2016.928,16.4588%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
媒體文章
了解權威媒體如何報道藥明康德賦能醫藥健康產業的專題文章、訪談，從第三方視角，展現藥明康德的CRDMO能力與對全球生命科學創新的貢獻。
了解權威媒體如何報道藥明康德賦能醫藥健康產業的專題文章、訪談，從第三方視角，展現藥明康德的CRDMO能力與對全球生命科學創新的貢獻。
筛选
全部年份
2026/04/07
媒體聲音｜探訪瑞士庫威基地：CRDMO模式如何加速全球創新轉化？
近日，藥明康德高級副總裁、製劑研發和生產業務部負責人陳金玲博士接受了德國媒體 VC Magazin 專訪。作為深耕行業二十餘年的資深專家，陳博士深入解讀了 CRDMO 模式的價值，並分享了瑞士庫威基地如何構建穩健的能力體系，以高效應對複雜研發挑戰。
閲讀更多2025/09/23
媒體聲音 | 藥明康德一體化CRDMO如何助力北歐創新發展？
近日，藥明康德新藥發現業務副總裁Dave Madge博士接受歐洲行業媒體《北歐生命科學新聞》（Nordic Life Science News）的採訪，他為斯堪的納維亞半島地區的創新活力而感到振奮，也提到，無論是初創企業，還是大型製藥公司，藥明康德的一體化CRDMO平臺都能為他們創造價值，助力當地創新生態圈的發展。
閲讀更多2025/09/01
對話陳民章博士：25年來，藥明康德如何加速新藥誕生？
在藥明康德成立25周年之際，陳民章博士應邀接受知名產業媒體BioWorld專訪，回顧公司的發展歷程，並分享藥明康德獨特的CRDMO業務模式如何為生物醫藥行業的客戶們降低研發門檻，提升研發效率，為全球病患帶來突破性的治療方案。
閲讀更多2025/08/22
25載平臺之路，Co-CEO陳民章博士談藥明康德如何賦能產業創新
日前，行業媒體Pharma Manufacturing的主編Greg Slabodkin採訪了公司聯席首席執行官陳民章博士。陳民章博士擁有二十多年新藥研發和生產管理經驗，在多個全球新藥的研發及商業化過程中發揮了重要作用。
閲讀更多2025/07/24
攻克“不可成藥”：楊青博士談創新療法的突破與合作
近日，藥明康德聯席首席執行官楊青博士與權威行業媒體STAT對談，分享了他對TPD如何改寫癌症和其他疾病治療前景的洞見，並對一體化CRDMO平臺在加速此類藥物研發方面的作用進行了深度解讀。
閲讀更多